Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376300 | 0.90 | OPRM1 (0.51) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL26347105 | 0.90 | OPRM1 (0.51) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL21744620 | 0.90 | OPRM1 (0.65) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| Hydrochloric Acid SCHEMBL31629842 | 0.88 | OPRM1 (0.66) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL8712547 | 0.81 | OPRM1 (0.55) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL2588468 | 0.80 | OPRM1 (0.61) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL2379073 | 0.80 | FUCA1 (0.52) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL20818826 | 0.78 | OPRM1 (0.49) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL20825939 | 0.78 | GRIN2B (0.49) | OPRM1OPRL1GRIN2BACHEBACE1 | |
| SCHEMBL1644281 | 0.78 | GRIN2B (0.49) | OPRM1OPRL1GRIN2BACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624309-B1 | Administering 4-heterocyclicbenzamide derivative | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | LLOYD JOHN (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137968-A1 | Benzoic acid derivatives and related compounds as antiarrhythmic agents | SCN1A, SCN1B, NR0B1 | OPRM1 384/4885OPRL1 292/4885GRIN2B 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.